Meeting
2013 ASCO Annual Meeting
Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.
Authors
Pallavi Sachdev
Eisai Inc., Woodcliff Lake, NJ
Pallavi Sachdev , Omid Hamid , Kevin Kim , Axel Hauschild , Steven O'Day , Corina Andresen , Yasuhiro Funahashi , Tadashi Kadowaki , James P. O'Brien , Keith Flaherty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01136967
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9058)
DOI
10.1200/jco.2013.31.15_suppl.9058
Abstract #
9058
Poster Bd #
46E
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer.
First Author: Yasuhiro Funahashi
Poster
2013 ASCO Annual Meeting
A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.
First Author: Steven O'Day
First Author: Ines Esteves Domingues Pires Da Silva
Poster
2014 ASCO Annual Meeting
Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.
First Author: Lindsay Carol Overton